Antisense Therapeutics -

. .

Résumé :
Announcement of the complete sequencing of the human genome in April 2003 demonstrated the presence of thousands of targets for antisense oligonucleotides and opened the way to hundreds of preclinical animal studies and some 20 ongoing clinical trials. In this second edition of Antisense Therapeutics, a team of leading researchers and clinical scientists demonstrate the new reality of antisense and RNA inhibition for treating a broad range of diseases. The authors show how antisense oligonucleotides are being designed and studied in relation to hypertension, various cancers, inflammatory bowel disease, brain disorders, the blood-brain barrier, and drug delivery. Highlights include RNA-based therapies for many diseases, up-to-date methods and applications, and insight into the enormous potential to provide a new generation of drugs.
Highly practical and disease oriented, Antisense Therapeutics, Second Edition offers not only a primer for a new generation of drug discovery researchers, but also an illuminating exploration of the potential in exploiting RNA inhibition for novel human therapeutics.

Sommaire:
Antisense Therapeutics.- Antisense Inhibition.- Cardiovascular.- Local Application of Antisense for Prevention of Restenosis.- Antisense Therapeutics for Hypertension.- Antisense Strategies for the Treatment of Heart Failure.- Cancer.- Clinical Studies of Antisense Oligonucleotides for Cancer Therapy.- Antisense Therapy in Clinical Oncology.- Radionuclide-Peptide Nucleic Acid in Diagnosis and Treatment of Pancreatic Cancer.- uppression of Pancreatic and Colon Cancer Cells by Antisense K-ras RNA Expression Vectors.- Induction of Tumor Cell Apoptosis and Chemosensitization by Antisense Strategies.- Utility of Antioncogene Ribozymes and Antisense Oligonucleotides in Reversing Drug Resistance.- Blood-Brain Barrier.- Transport of Antisense Across the Blood-Brain Barrier.- Dermal.- Transdermal Delivery of Antisense Oligonucletoides.- Drugs.- Antisense Strategies for Redirection of Drug Metabolism.- Gastrointestinal.- Antisense Oligonucleotide Treatment of Inflammatory Bowel Diseases.- Hepatitis.- Optimizing Electroporation Conditions for Intracellular Delivery of Morpholino Antisense Oligonucleotides Directed Against the Hepatitis C Virus Internal Ribosome Entry Site.